pharma · Chemotherapy Induced Neuropathic Pain · DWTX
Dogwood Therapeutics
Dogwood Therapeutics patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Alpharetta, USA
- Founded
- 2020
- Employees
- 9
- Programs
- 1
- Drugs
- 2
- Patents
- 7
Dogwood Therapeutics patents
7 pharmaceutical patents indexed for Dogwood Therapeutics. 0 expire within 24 months.
Dogwood Therapeutics has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 9446021
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
granted -
US 9120754
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
granted -
US 8349848
Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors
granted -
US 8293720
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
granted -
US 8263762
Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists
granted -
US 8258142
Substituted 8-[6-amino-3-pyridyl]xanthines
granted -
US 8252767
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
granted
Frequently asked questions
How many patents does Dogwood Therapeutics have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Dogwood Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.